Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023
09 August 2023 - 2:47PM
Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the
"Company"), a biotechnology company developing therapeutic
candidates targeting drug resistant and devastating cancers using
ferroptosis, an emerging new anti-cancer mechanism resulting in
iron-mediated cell death, and immuno-oncology targeted novel
biologics, today announced that it will be attending the
Annual Sidoti Micro-Cap Virtual Conference being held on
August 16-17, 2023.
“We’ve made a lot of progress since we’ve announced the
strategic reprioritization of our drug pipeline making this an
opportune time to share updates with the investment community,”
says Randy Milby, CEO of Hillstream. “Sidoti has fostered a strong
tight knit group of movers and shakers within the micro-cap world,
and we believe this group will be a good fit for understanding our
true value proposition as we continue to make advancements with our
HER2/HER3 program and transform Hillstream into a focused and
targeted cancer biologics company.”
The Company recently announced its expansion of collaboration
with Minotaur Therapeutics, Inc. and of its license agreement with
OmniAb, Inc. to propel the advancement of next generation targeted
Knob biologics (Picobodies™) development against HER3 and a new
undisclosed oncology target. This will in turn complement
Hillstream’s HSB-3215 program.
To schedule a meeting with the management team or view the
presentation, please send an email
to investorrelations@hillstreambio.com or visit
https://www.meetmax.com/sched/event_96493/investor_reg_new.html?attendee_role_id=SIDOTI_INVESTOR.
About Hillstream BioPharma Inc.Hillstream
BioPharma, Inc. is a biotechnology company developing a focused
portfolio of therapeutic candidates targeting drug resistant and
devastating cancers. The Company’s emerging immuno-oncology
pipeline is led by HSB-3215, a novel anti-HER2/HER3 monoclonal
antibody targeting unique epitopes with a novel mechanism of
action. The erbB/HER family of cell surface proteins include
well-known and validated drug targets including HER2 and HER3 found
in multiple solid tumors, including breast, lung, GYN,
endocrinological and CNS. Hillstream has a license agreement with
OmniAb, Inc. to access the company’s antibody discovery technology
platform against specified targets. For more information, please
visit: www.hillstreambio.com.
Forward Looking StatementsCertain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified using words such as “anticipate,” “believe,”
“forecast,” “estimated” and “intend” or other similar terms or
expressions that concern Hillstream’s expectations, strategy, plans
or intentions. These forward-looking statements are based on
Hillstream’s current expectations and actual results could differ
materially. There are several factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, clinical trials involve a lengthy and expensive process
with an uncertain outcome, and results of earlier studies and
trials may not be predictive of future trial results; our clinical
trials may be suspended or discontinued due to unexpected side
effects or other safety risks that could preclude approval of our
product candidates; risks related to business interruptions,
including the outbreak of COVID-19 coronavirus, which could
seriously harm our financial condition and increase our costs and
expenses; dependence on key personnel; substantial competition;
uncertainties of patent protection and litigation; dependence upon
third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations.
Investors should read the risk factors set forth in our Form 10-K
for the year ended December 31, 2022, and our periodic reports
filed with the Securities and Exchange Commission. While the list
of factors presented here is considered representative, no such
list should be considered to be a complete statement of all
potential risks and uncertainties. Unlisted factors may present
significant additional obstacles to the realization of
forward-looking statements. Forward-looking statements included
herein are made as of the date hereof, and Hillstream does not
undertake any obligation to update publicly such statements to
reflect subsequent events or circumstances.
“Picobody” is a trademark of Crystal Bioscience, Inc., a unit of
OmniAb, Inc.
Investor Relations
ContactEmail: investorrelations@hillstreambio.comwww.hillstreambio.com
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024